Using Mirabegron to treat intracerebral hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of Mirabegron, a β3 adrenergic receptor agonist, in patients suffering from intracerebral hemorrhage (ICH). The research aims to determine if Mirabegron can reduce neuroinflammation and brain edema, potentially improving neurological outcomes. Participants will receive standard treatment along with Mirabegron or standard treatment alone. The study focuses on patients with specific criteria, including a hematoma volume of 5-30 ml and a Glasgow Coma Scale score between 6 and 12.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female patients aged above 18 years old.
2. The volume of the hematoma is 5-30 ml (including the cerebral cortex; Putamen, thalamus, caudate nucleus and related deep tracts; Cerebellar hemorrhage), which determined by CT scan.
3. The onset of cerebral hemorrhage symptoms or the time from last normal to detection is not more than 72 hours.
4. Patients with Glasgow Coma Scale (GCS) score ≥6 and \< 12.
5. Before the onset of the disease, function was independent and mRS score\<1.
6. Able and willing to sign written informed consent and comply with the requirements of the research protocol.

Exclusion criteria:

1. Multifocal cerebral hemorrhage, brain stem hemorrhage, or ventricular hemorrhage.
2. Secondary cerebral hemorrhage caused by aneurysm, brain tumor, arteriovenous malformation, thrombocytopenia, coagulation disorder, traumatic brain injury, etc.
3. Patients who require hematoma removal surgery or other emergency surgical interventions (such as decompressive craniectomy), or who are critically ill and close to death.
4. Patients who interfere with drug use due to nausea or vomiting.
5. Combined with the following conditions that preclude participation in the study due to other systemic diseases: Severe hepatic or renal impairment, atrial fibrillation or tachycardia, pulmonary infection, severe urinary tract infection, severe urinary tract obstruction, medically uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg), pregnant and lactating women, and a history of malignant tumors within 5 years.

Where it's running

• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Handong Li
• Email: handongli90@foxmail.com
• Phone: +8615022439149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Savvy medication-support program for people after stroke

  This project will test whether Savvy — short phone-based psychological exercises, a weekly pill organizer, and text reminders — helps stroke survivors take their blood-pressure medicines and improve blood pressure compared with usual care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07414732

• AI-assisted transcranial Doppler ultrasound to detect early brain bleeding

  This will try to see if a quick transcranial Doppler ultrasound combined with artificial intelligence can detect intracerebral bleeding in adults with suspected acute stroke within 48 hours of symptom onset.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Catalonia · NCT07319013

• Reducing the risk of heart and brain events after intracerebral hemorrhage with aspirin

  This trial tests whether giving low-dose aspirin every day after intracerebral hemorrhage can reduce major heart or brain-related events compared with a placebo.

  Recruiting at 33 sites Phase 3 Christian Medical College and Hospital, Ludhiana, India · Guntur, Andhra Pradesh and 32 other locations · NCT07243704

• Minimally invasive surgery to remove deep (basal ganglia) brain hemorrhages

  This observational study will see if minimally invasive surgery helps adults aged 18–80 with spontaneous deep (basal ganglia) intracerebral hemorrhage who present within 72 hours, compared with standard medical care.

  Recruiting 115 People's Hospital · Ho Chi Minh City, Ho Chi Minh · NCT07234955

• Stereotactic tenecteplase clot liquefaction for supratentorial intracerebral hemorrhage

  This trial will see if stereotactic minimally invasive clot drainage plus a single low dose of tenecteplase helps adults with moderate-to-large supratentorial intracerebral hemorrhage recover better than standard medical care.

  Recruiting at 51 sites Tongji Hospital · Anqing, Anhui and 50 other locations · NCT07208097

• When and how people recover after an intracerebral hemorrhage

  This registry will collect detailed, long-term data on adults who have surgery for intracerebral hemorrhage to see if the timing and type of surgical treatment affect recovery and quality of life.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07166146

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.